Last updated: July 17, 2026

Application No. 18/343,502

TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS

Non-Final OA

Filed

Jun 28, 2023

Priority

Mar 16, 2016 — provisional 62/308,970 +4 more

Examiner

SKELDING, ZACHARY S

Art Unit

1644

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Immatics Biotechnologies GmbH

OA Round

1 (Non-Final)

Interview Optional

— +41.4% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 60% grant rate with +41.4% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.

Based on 828 resolved cases, 2023–2026

Examiner Intelligence

SKELDING, ZACHARY S View full profile →

Grants 60% of resolved cases

Career Allowance Rate

494 granted / 828 resolved

At TC average

Strong +41% interview lift

Without

With

+41.4%

Interview Lift

resolved cases with interview

Typical timeline

3y 7m

Avg Prosecution

39 currently pending

Career history

860

Total Applications

across all art units

Statute-Specific Performance

§101

1.8%

-38.2% vs TC avg

§103

32.8%

-7.2% vs TC avg

§102

10.0%

-30.0% vs TC avg

§112

34.9%

-5.1% vs TC avg

Black line = Tech Center average estimate • Based on career data from 828 resolved cases

Prosecution Timeline

Jun 28, 2023

Application Filed

Jun 01, 2026

Examiner Interview (Telephonic)

Jun 05, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/310,141

Patent 12673981

T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS

3y 2m to grant Granted Jul 07, 2026

17/774,333

Patent 12668641

ANTIBODY VARIANT COMBINATIONS AND USES THEREOF

4y 1m to grant Granted Jun 30, 2026

18/066,791

Patent 12655218

IMMUNOGLOBULINS BINDING HUMAN VGAMMA9VDELTA2 T CELL RECEPTORS

3y 6m to grant Granted Jun 16, 2026

18/174,928

Patent 12630802

METHODS OF ISOLATING T CELLS AND T CELL RECEPTORS HAVING ANTIGENIC SPECIFICITY FOR A CANCER-SPECIFIC MUTATION FROM PERIPHERAL BLOOD

3y 2m to grant Granted May 19, 2026

17/791,056

Patent 12617860

ANTI-TNFR2 ANTIBODY AND USES THEREOF

3y 10m to grant Granted May 05, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

60%

Grant Probability

99%

With Interview (+41.4%)

3y 7m (~7m remaining)

Median Time to Grant

Low

PTA Risk

Based on 828 resolved cases by this examiner. Grant probability derived from career allowance rate.